BACKGROUND: Despite antiplatelet therapy, some patients remain at high ischemic risk because of drug nonresponsiveness or high residual platelet reactivity). We aimed to target an orphan platelet GPCR ...
More than half of patients with myelofibrosis and low platelets treated with Vonjo saw platelets rise 58% and hemoglobin levels improve. More than half of patients with low platelets (thrombocytopenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results